A phase III clinical trial led by an investigator at the Medical University of South Carolina found that a novel four-month regimen was just as effective at treating tuberculosis as the standard six-month regimen. The findings are reported in the May 6, 2021 New England Journal of Medicine.
MUSC Hollings Cancer Center researchers are finding solutions to the aging-related changes that reduce anti-cancer immunity. Their work, published in Cell Reports, sheds light on an important pathway that cannot be ignored during cancer treatment.
MUSC Hollings Cancer Center researcher Haizhen (Jen) Wang, Ph.D., recently was awarded a three-year $225,000 Young Investigator grant from the Melanoma Research Alliance. The grant will help Wang further her research on T-cells and the tumor microenvironment in melanoma patients.
Hollings researchers found a modified peptide carrier that was delivering the siRNA drug by adhering to and potentially moving along cell filopodia, leading to more efficient cell entry and improved gene silencing.
E-Mail
IMAGE: Dr. Gerard Silvestri was very surprised by his findings, as younger patients typically have better outcomes than their older counterparts with similar stages and types of cancer. view more
Credit: MUSC
MUSC Hollings Cancer Center lung cancer researcher Gerard Silvestri, M.D., found that a lack of insurance leads to worse cancer survival than for those with Medicare, in a paper published in the May issue of
Health Affairs. This work, a joint effort between Silvestri and researchers at the American Cancer Society, highlights the current dire barrier in medical care: Many people cannot take advantage of the newer potentially lifesaving treatments due to the high costs.